# Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

> **NCT00916409** · PHASE3 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 700 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DEVICE:** NovoTTF-100A device
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00916409
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916409, "Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00916409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*